Latest Period
Q4 2025
Security Snapshot
Abivax S.A. - Ordinary Shares, nominal value Euro 0.01 per share (ABVX) Institutional Ownership
CUSIP: 00370M103
13F Institutional Holders and Ownership History from Q4 2023 to Q1 2026
Institutions Reporting
247
Shares (Excl. Options)
56,312,422
Price
$134.86
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Ordinary Shares, nominal value Euro 0.01 per share
- Symbol
- ABVX on Nasdaq
- Shares outstanding
- 78,459,900
- Price per share
- $119.47
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 56,312,422
- Total reported value
- $7,607,004,075
- % of total 13F portfolios
- 0.03%
- Share change
- +3,845,855
- Value change
- +$630,821,272
- Number of holders
- 247
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- ABVX - Abivax S.A. - Ordinary Shares, nominal value Euro 0.01 per share is tracked under CUSIP 00370M103.
- 247 institutions reported positions in Q4 2025.
- 5 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 247 to 54 between Q4 2025 and Q1 2026.
- Reported value moved from $7,607,004,075 to $147,999,890.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 247 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 00370M103?
CUSIP 00370M103 identifies ABVX - Abivax S.A. - Ordinary Shares, nominal value Euro 0.01 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 00370M103:
Significant Owners of Abivax S.A. - Ordinary Shares, nominal value Euro 0.01 per share (ABVX) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| TCG Crossover GP I, LLC | 9.1% | $603,774,500 | 7,111,596 | Chen Yu | 30 Sep 2025 | |||
| Sofinnova Crossover I | 7.7% | -19% | $863,002,246 | -$269,710,200 | 6,399,478 | -24% | Sofinnova Crossover I SLP | 12 Jan 2026 |
| Invus Global Management, LLC | 5% | -39% | $469,347,122 | -$177,185,644 | 3,922,995 | -27% | Invus Public Equities, L.P. | 31 Dec 2025 |
| Deep Track Capital, LP | 4.8% | $28,885,195 | 3,480,144 | Deep Track Capital, LP | 30 Jun 2025 | |||
| Venrock Healthcare Capital Partners III, L.P. | 0.8% | $48,964,292 | 576,729 | Venrock Healthcare Capital Partners III, L.P. | 30 Sep 2025 |
As of 31 Dec 2025, 247 institutional investors reported holding 56,312,422 shares of Abivax S.A. - Ordinary Shares, nominal value Euro 0.01 per share (ABVX). This represents 72% of the company’s total 78,459,900 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Abivax S.A. - Ordinary Shares, nominal value Euro 0.01 per share (ABVX) together control 50% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| TCG Crossover Management, LLC | 9.1% | 7,111,596 | 0% | 32% | $959,034,279 |
| UBS Group AG | 5.6% | 4,423,906 | -0.84% | 0.12% | $596,585,843 |
| Darwin Global Management, Ltd. | 4.1% | 3,178,501 | +0.44% | 8.9% | $439,713,828 |
| MORGAN STANLEY | 4% | 3,151,994 | +114% | 0.03% | $425,062,151 |
| Point72 Asset Management, L.P. | 3.1% | 2,409,154 | -18% | 0.51% | $324,886,463 |
| Vestal Point Capital, LP | 2.4% | 1,900,000 | +90% | 9.4% | $256,224,500 |
| Caligan Partners LP | 1.9% | 1,451,924 | 0% | 18% | $195,799,211 |
| Paradigm Biocapital Advisors LP | 1.8% | 1,417,473 | -9.4% | 5.1% | $191,153,321 |
| FMR LLC | 1.7% | 1,365,657 | -4.5% | 0.01% | $184,165,674 |
| Cormorant Asset Management, LP | 1.7% | 1,350,000 | -31% | 10% | $182,054,250 |
| ADAR1 Capital Management, LLC | 1.7% | 1,317,329 | -2.5% | 13% | $177,648,402 |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 1.3% | 1,009,966 | 0.57% | $136,198,965 | |
| BAKER BROS. ADVISORS LP | 1.1% | 875,796 | 0% | 0.69% | $118,105,470 |
| LORD, ABBETT & CO. LLC | 1.1% | 849,732 | +152% | 0.35% | $114,591,000 |
| DEUTSCHE BANK AG\ | 0.97% | 764,899 | 0.03% | $103,154,279 | |
| Octagon Capital Advisors LP | 0.96% | 756,000 | -43% | 13% | $101,950,380 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.96% | 754,836 | +2081% | 0.14% | $101,793,409 |
| MILLENNIUM MANAGEMENT LLC | 0.94% | 741,060 | -33% | 0.07% | $99,935,646 |
| Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. | 0.88% | 691,973 | -5.4% | 8.3% | $93,316,019 |
| JANUS HENDERSON GROUP PLC | 0.85% | 667,761 | +88% | 0.04% | $90,037,554 |
| Eversept Partners, LP | 0.84% | 657,834 | +54% | 5% | $88,712,204 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 0.83% | 651,644 | +36% | 0.01% | $87,875,000 |
| Saturn V Capital Management LP | 0.83% | 649,179 | -19% | 16% | $87,545,034 |
| Artia Global Partners LP | 0.77% | 600,747 | +166% | 13% | $81,013,737 |
| CITADEL ADVISORS LLC | 0.72% | 563,747 | -17% | 0.05% | $76,024,102 |
Institutional Holders of Abivax S.A. - Ordinary Shares, nominal value Euro 0.01 per share (ABVX) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 1,333,663 | $147,999,890 | +$18,805,027 | $111.35 | 54 |
| 2025 Q4 | 56,312,422 | $7,607,004,075 | +$630,821,272 | $134.86 | 247 |
| 2025 Q3 | 51,964,814 | $4,408,157,076 | +$2,126,922,733 | $84.90 | 165 |
| 2025 Q2 | 30,664,346 | $234,581,803 | -$5,694,979 | $7.65 | 43 |
| 2025 Q1 | 31,761,546 | $198,509,815 | +$9,164,590 | $6.25 | 46 |
| 2024 Q4 | 29,861,029 | $218,582,712 | +$7,328,424 | $7.32 | 47 |
| 2024 Q3 | 27,383,884 | $312,847,988 | -$8,252,199 | $11.52 | 40 |
| 2024 Q2 | 28,098,910 | $371,643,391 | +$62,450,093 | $13.22 | 38 |
| 2024 Q1 | 23,372,028 | $334,151,423 | +$31,771,567 | $14.30 | 36 |
| 2023 Q4 | 21,265,859 | $227,821,381 | +$227,821,381 | $10.70 | 30 |